Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 970 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Completed Not applicable Interventional Results available

Valproate for Mood Swings and Alcohol Use Following Head Injury

NCT01760785
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Alcoholism
Interventions
divalproex sodium, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 10, 2026, 7:42 AM EDT
Recruiting Phase 3 Interventional

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Pasritamig, Docetaxel, Prednisone/Prednisolone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
59
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

NCT01321554
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
38
States / cities
Little Rock, Arkansas • La Jolla, California • Los Gatos, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI)
Drug · Other · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 10, 2026, 7:42 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT03421145
View directory record Official record
Conditions
Plaque
Interventions
3M™ Oral Rinse, Vehicle Control Oral Rinse, PerioShield™ Oral Health Rinse, Water
Device · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

NCT03063606
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 10, 2026, 7:42 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Normal Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
3,547 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 10, 2026, 7:42 AM EDT
Not listed Phase 3 Interventional

A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty

NCT04298528
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Dronabinol, Placebo
Drug · Other
Lead sponsor
Colorado Joint Replacement
Other
Eligibility
21 Years to 75 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01497899
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 10, 2026, 7:42 AM EDT
Not yet recruiting Not applicable Interventional

Argus 2.0 Adoption Study

NCT07425236
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
Interventions
KOS Argus Continuous Glucose Monitoring System
Device
Lead sponsor
KOS Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 10, 2026, 7:42 AM EDT
Active, not recruiting Phase 1 Interventional

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

NCT06402565
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
NOX1416 and SOC, SOC (Standard of care)
Drug · Procedure
Lead sponsor
NOxy Health Products, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

NCT00870311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram Pill, Placebo, Levomilnacipran Pill
Drug · Other
Lead sponsor
Howard Aizenstein
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Tranexamic Acid in Reduction Mammoplasty

NCT04947514
View directory record Official record
Conditions
Hematoma Postoperative, Venous Thromboembolism
Interventions
Tranexamic acid, Placebo (topical saline)
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 10, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 10, 2026, 7:42 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

NCT06731075
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 10, 2026, 7:42 AM EDT
Recruiting Phase 3 Interventional

Cognitive Strategies in Early Psychosis 2

NCT07263022
View directory record Official record
Conditions
Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions
Modafinil, D-serine solution, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 10, 2026, 7:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The PREVENT Resilience Study

NCT07568145
View directory record Official record
Conditions
Psychological Trauma
Interventions
Transcranial Magnetic Stimulation (TMS), TMS Sham
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 7:42 AM EDT